Related Experiment Videos
Antiaggregation effect of alum on human platelets
1Department of Physiology and Biochemistry, Faculty of Medicine, University of Jordan, Amman. fmmed@ju.edu.jo
Summary
Alum effectively inhibits human platelet aggregation induced by collagen, epinephrine, ADP, and thrombin in a dose-dependent manner. However, it does not affect aggregation induced by ristocetin, suggesting a specific anti-platelet action.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Platelet aggregation is a critical process in hemostasis and thrombosis.
- Understanding agents that modulate platelet function is crucial for managing bleeding disorders and thrombotic events.
Purpose of the Study:
- To investigate the impact of alum on human platelet aggregation.
- To determine the dose-dependent effects of alum on platelet aggregation induced by various agonists.
Main Methods:
- Human platelet-rich plasma was isolated from healthy male volunteers.
- Platelet aggregation was stimulated using collagen, epinephrine, ADP, thrombin, and ristocetin.
- Aggregation percentages were measured in the presence and absence of varying alum concentrations.
Main Results:
- Alum demonstrated a dose-dependent inhibition of platelet aggregation induced by collagen, epinephrine, ADP, and thrombin.
- The IC50 values for alum ranged from 0.191 to 0.668 mg/ml for these agonists.
- Ristocetin-induced platelet aggregation remained unaffected by alum up to 1.5 mg/ml.
Conclusions:
- Alum exhibits significant anti-platelet activity against multiple aggregation pathways.
- Caution is advised when using alum for intractable intravesical hemorrhage due to its anti-platelet effects.
- Alum presents a cost-effective option for anti-platelet therapy, warranting further research.